In the present study, we demonstrate that knockdown of OLFML2B in CAFs attenuates its tumor-promoting effects on HepG2 cell proliferation and invasion, suggesting that OLFML2B is a potential therapeutic target in HCC. Here, OLFML2B is linked to hepatocellular carcinoma.